ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche invests in Dyno’s viral vectors

by Michael McCoy
October 17, 2020 | APPEARED IN VOLUME 98, ISSUE 40

 

Roche is licensing technology from the start-up Dyno Therapeutics for making the adeno-associated virus (AAV) vectors needed to deliver gene therapies to cells. Under the deal, Dyno will get an undisclosed up-front payment and up to $1.8 billion in milestones. In exchange, Dyno will use its CapsidMap technology to design AAV capsids for gene therapies from Roche and Roche’s Spark Therapeutics subsidiary. Target applications are diseases of the central nervous system and liver-directed therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment